Table 1.
Baseline characteristics of patients with fracture ≥1 year in comparison to those without fracture
| Fracture | Nonfracture | Unadjusted P | Age-, Gender-, and Diabetes-Adjusted P | |
|---|---|---|---|---|
| n | 23 | 59 | ||
| eGFR, ml/min, median (IQR) | 25 (14 to 35) | 28 (19 to 41) | NS | |
| Age, years, median (IQR) | 78 (66 to 84) | 69 (62 to 76) | 0.006 | |
| BMI, median (IQR) | 27.1 (24.2 to 30.9) | 29.3 (26.1 to 33.8) | NS | |
| Years since nonspine fracture, median (IQR) | 7.9 (2.1 to 9.8) | NA | ||
| Gender, % female | 57 | 39 | NS | |
| Race, % | ||||
| white | 48 | 59 | NS | |
| black | 42 | 40 | NS | |
| ethnicity, % | ||||
| Hispanic | 52 | 58 | NS | |
| non-Hispanic | 48 | 52 | NS | |
| Diabetes, % | 39 | 68 | 0.02 | |
| Duration of CKD, years, median (IQR) | 5.0 (3.4 to 10.0) | 5.5 (3.4 to 9.3) | NS | |
| Laboratory parameters, median (IQR) | ||||
| serum calcium, mg/dl | 9.4 (8.9 to 9.8) | 9.3 (9.0 to 9.7) | NS | |
| serum phosphorus, mg/dl | 3.7 (3.3 to 4.7) | 3.6 (3.0 to 4.2) | NS | |
| serum bicarbonate, mM/L | 22 (21 to 26) | 23 (22 to 25) | NS | |
| Medications, % | ||||
| calcium-containing agents | 26 | 21 | NS | |
| noncalcium-containing phosphate binding agents | 17 | 18 | NS | |
| vitamin D—parent | 70 | 63 | NS | |
| vitamin D—active | 35 | 32 | NS | |
| Behaviors, % | ||||
| current alcohol use | 13 | 10 | NS | |
| current tobacco use | 9 | 7 | NS | |
| DXA measurements, median (IQR)a | ||||
| LS aBMD, g/cm2 | 0.938 (0.853 to 1.057) | 1.060 (0.957 to 1.216) | 0.006 | NS |
| LS T-score | −1.4 (−2.1; −0.2) | −0.1 (−1.1 to 1.2) | 0.01 | 0.04 |
| TH aBMD, g/cm2 | 0.783 (0.728 to 0.878) | 0.943 (0.805 to 1.069) | 0.004 | NS |
| TH T-score | −1.5 (−2.1; −0.6) | −0.6 (−1.6 to 0.3) | 0.007 | NS |
| FN aBMD, g/cm2 | 0.621 (0.569 to 0.666) | 0.747 (0.667 to 0.848) | 0.0009 | NS |
| FN T-score | −2.2 (−2.7; −1.4) | −1.4 (−2.1; −0.8) | 0.002 | 0.03 |
| 1/3R aBMD, g/cm2 | 0.630 (0.549 to 0.714) | 0.773 (0.634 to 0.805) | 0.001 | NS |
| 1/3R T-score | −1.8 (−3.1; −0.6) | −0.9 (−2.1 to 0.06) | 0.006 | 0.02 |
| UDR aBMD, g/cm2 | 0.340 (0.302 to 0.415) | 0.442 (0.369 to 0.503) | <0.0001 | 0.005 |
| UDR T-score | −2.2 (−3.4; −1.2) | −1.2 (−1.8; −0.5) | 0.009 | 0.007 |
| HR-pQCT measurements distal radius, median (IQR) | ||||
| cross-sectional area, mm2 | 278 (235 to 314) | 300 (236 to 357) | NS | NS |
| cortical area, mm2 | 40 (35 to 48) | 55 (46 to 72) | 0.0001 | 0.01 |
| cortical thickness, μm | 610 (480 to 710) | 750 (600 to 930) | <0.0001 | 0.02 |
| total density, mg HA/cm3 | 248 (209 to 299) | 308 (268 to 347) | <0.0001 | 0.006 |
| cortical density, mg HA/cm3 | 795 (724 to 850) | 842 (781 to 910) | 0.006 | NS |
| trabecular density, mg HA/cm3 | 114 (86 to 161) | 154 (130 to 189) | 0.002 | 0.02 |
| trabecular number, 1/mm | 1.7 (1.4 to 2.1) | 2.0 (1.8 to 2.3) | 0.04 | NS |
| trabecular thickness, μm | 59 (48 to 69) | 65 (60 to 68) | 0.02 | 0.03 |
| trabecular heterogeneity (μm) | 237 (165 to 359) | 178 (151 to 201) | 0.03 | NS |
| HR-pQCT measurements distal tibia, median (IQR) | ||||
| cross-sectional area, mm2 | 783 (624 to 866) | 782 (642 to 863) | NS | NS |
| cortical area, mm2 | 80 (56 to 89) | 113 (84 to 138) | <0.0001 | 0.01 |
| cortical thickness, μm | 690 (500 to 810) | 1005 (820 to 1210) | <0.0001 | 0.01 |
| total density, mg HA/cm3 | 222 (186 to 244) | 257 (224 to 304) | 0.0002 | 0.03 |
| cortical density, mg HA/cm3 | 718 (662 to 802) | 797 (752 to 846) | 0.002 | 0.04 |
| trabecular density, mg HA/cm3 | 150 (119 to 158) | 161 (131 to 186) | NS | NS |
| trabecular number, 1/mm | 1.7 (1.5 to 1.9) | 1.9 (1.7 to 2.2) | NS | NS |
| trabecular thickness, μm | 69 (60 to 73) | 69 (61 to 77) | NS | NS |
| trabecular heterogeneity (μm) | 245 (206 to 295) | 193 (161 to 264) | NS | NS |
BMI, body mass index; IQR, interquartile range.
aT-scores are only adjusted for age and diabetes status.